Warfarin Anticoagulant Therapy: A Southern Italy Pharmacogenetics-Based Dosing Model

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Mazzaccara, Cristina ^a,b   Conti, Valeria ^c   Liguori, Rosario ^a,b   Simeon, Vittorio ^d   Toriello, Mario ^b   Severini, Angelo ^b   Perricone, Corrado ^e   Meccariello, Alfonso ^b   Meccariello, Pasquale ^b   Vitale, Dino Franco ^f   Filippelli, Amelia ^c   Sacchetti, Lucia ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^f IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DOSE RESPONSE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; SEQUENCE ANALYSIS; SEX DIFFERENCE;

AGED; ALGORITHMS; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; ITALY; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; REGRESSION ANALYSIS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84883183513     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071505     Document Type: Article

References (50)

1. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, et al. (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8 (11):: 1545-50.
2. Kim M, Huang SM, Meyer UA, Rahman A, Lesko LJ, (2009) A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 49 (2):: 138-46.
3. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5 (3):: 1-9.
4. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, et al. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90 (4):: 625-9.
5. Fareed J, Thethi I, Hoppensteadt D, (2012) Old Versus New Oral Anticoagulants: Focus on Pharmacology. AnnRev Pharmacol Toxicol 52: 79-99.
6. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ, (2012) Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) versus Warfarin in Patients with Atrial Fibrillation. Am J Cardiol 110: 453-460.
7. Ansell J, (2010) Warfarin Versus New Agents: Interpreting the Data. Hematology Am Soc Hematol Educ Program 2012: 221-8.
8. Kamali F, Wynne H, (2010) Pharmacogenetics of warfarin. Annu Rev Med 61: 63-75.
9. Keeling D, Baglin T, Tait C, Watson, Perry D, et al. (2009) Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 66 (2):: 123-33.
10. Gulseth MP, Grice GR, Dager WE, (2009) Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 66 (2):: 123-33.
11. Bon Homme M, Reynolds KK, Valdes R Jr, Linder MW, (2008) Dynamic pharmacogenetic models in anticoagulation therapy. Clin Lab Med 28 (4):: 539-52.
12. Kurnik D, Loebstein R, Halkin H, Gak E, Almog S, (2009) 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 10 (12):: 1955-65.
13. Teh LK, Langmia IM, Fazleen Haslinda MH, Ngow HA, Roziah MJ, et al. (2012) Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. J Clin Pharm Ther 37 (2):: 232-6.
14. Hill CE, Duncan A, (2008) Overview of pharmacogenetics in anticoagulation therapy. Clin Lab Med 28 (4):: 513-24.
15. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 329 (7456):: 15-9.
16. Mahajan P, Meyer KS, Wall GC, Price HJ, (2011) Clinical applications of pharmacogenomics guided warfarin dosing. Int J Clin Pharm 33 (1):: 10-9.
17. Burmester JK, Berg RL, Glurich I, Yale SH, Schmelzer JR, et al. (2011) Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses. Clin Med Res 9 (3-4):: 119-24.
18. You JH, (2011) Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin. Pharmacoter 12 (3):: 435-441.
19. Wu AH, (2011) Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics Jul 28,8 (1):: 12.
20. Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, et al. (2012) The Population Pharmacokinetics of R and S-Warfarin: Effect of Genetic and Clinical Factors. Br J Clin Pharmacol 73 (1):: 66-76.
21. Pavani A, Naushad SM, Rupasree Y, Kumar TR, Malempati AR, et al. (2012) Optimization of warfarin dose by population-specific pharmacogenomic algorithm. Pharmacogenomics J 12 (4):: 306-11.
22. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, et al. (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427 (6974):: 541-4.
23. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111 (8):: 4106-12.
24. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, et al. (2008) A genome-wide scan for common gentic variants with a large influence on warfarin maintenance dose. Blood 112 (4):: 1022-7.
25. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE, (2009) CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75 (6):: 1337-46.
26. Kringen MK, Haug KB, Grimholt RM, Stormo C, Narum S, et al. (2011) Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol 2011: 739751.
27. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, et al. (2011) Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118 (11):: 3163-71.
28. Liang R, Wang C, Zhao H, Huang J, Hu D, et al. (2012) Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. Thromb Res Jul,130 (1):: 38-44.
29. Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, et al. (2012) Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 92 (6):: 746-56.
30. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE, (2011) Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 57 (5):: 612-8.
31. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf.Accessed 2013 Mar.
32. Suarez-Kurtz G, (2011) Population diversity and the Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 72 (3):: 451-3.
33. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, et al. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10 (2):: 261-6.
34. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, et al. (2011) VKORC1,CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing:an Italian retrospective study. Pharmacogenomics 12 (1):: 15-25.
35. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2):: 645-9.
36. Cini M, Legnani C, Cosmi B, Guazzaloca G, Valdrè L, et al. (2012) A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol 68 (8):: 1167-74.
37. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ, (2010) Combined CYP2C9,VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11 (6):: 781-91.
38. Yang L, Ge W, Yu F, Zhu H, (2010) Impact of VCORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res 125 (4):: e159-66.
39. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, et al. (2008) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European American and African Americans. Pharmacogenomics 9 (5):: 511-526.
40. Gage BF, Lesko LJ, (2008) Pharmogenetics of warfarin: regulatory,scientific,and clinical issues. J Thromb Thrombolysis 25 (1):: 45-51.
41. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, et al. (2010) Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 55 (9):: 582-9.
42. Sanderson S, Emery J, Higgins J, (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7 (2):: 97-104.
43. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, et al. (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115 (18):: 3827-34.
44. Leitner JM, Mannhalter C, Jilma B, (2008) Genetic variations and their influence on risk and treatment of venous thrombosis. Pharmacogenomics 9 (4):: 423-37.
45. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, et al. (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87 (5):: 572-8.
46. International Warfarin Pharmacogenetics Consortium (2009) Klein TE, Altman RB, Eriksson N, Gage BF, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360 (8):: 753-64.
47. Livak KJ, (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14 (5-6):: 143-9.
48. Kutyavin IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, et al. (2000) 3′-minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 28 (2):: 655-61.
49. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview:analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2):: 263-5.
50. Gould WW, (1995) Jackknife estimation. Stata Technical Bulletin 24, sg34: 25-29.